EGFR and lung carcinoma: No clinical trials of EGFR-targeted NPs in lung cancer have been identified to date but three trials using anti-EGFR immunoliposomes containing Doxorubicin (anti-EGFR ILs-dox) were conducted for the treatment of other types of cancer [159].